Text Size

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00546624
First received: October 17, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted

October 17, 2007
October 17, 2007
November 2002
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD
Not Provided

This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Anxiety Disorder
Drug: MK0777
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
December 2003
Not Provided

Inclusion Criteria:

  • Have been diagnosed with Generalized Anxiety Disorder
  • Women of childbearing potential must use a double-barrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study

Exclusion Criteria:

  • History of drug or alcohol abuse
  • Have previously participated in another study using MK0777
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00546624
2007_632
Not Provided
Not Provided
Merck
Not Provided
Study Director: Medical Monitor Merck
Merck
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP